RightFit
RecruitingPhase not listed

Prostate Cancer Screening for People at Genetic Risk for Aggressive Disease, PATROL Study

PATROL: Prostate Cancer Screening for People AT Genetic Risk FOr Aggressive Disease

Who can join

As published by the study on ClinicalTrials.gov. "Not stated" means the study hasn't said — ask the study team.

Age
40 Years and older
Sex
Male only
Healthy volunteers
Accepted
Compensation
Not stated

Other requirements are listed under Eligibility below. Only the study team can confirm whether you can join.

What to expect

No one can promise a trial will help you personally — that is what the research is trying to find out.

What participation involves

  • Time periods mentioned: 3 years
  • Procedures mentioned: Biopsies

Only what the study's summary and detailed description on ClinicalTrials.gov say. Time periods may describe the whole study or a part of it — ask the study team what applies to you.

Show the study's own words
  • "OUTLINE: Participants undergo collection of blood, urine, and/or tissue samples every 6-12 months, when any biopsy occurs, and if relevant, at time of curative therapy and 3-9 months after completion of curative therapy for up to 3 years."
Compensation
Not stated
  • Study-related exams and procedures are typically provided at no cost. This is how many trials work in general — confirm the details for this study with the study team.
  • Participants are monitored closely by the research team throughout the study.
  • Some participants may receive access to an investigational treatment, which is still being studied.
  • Your participation helps researchers learn whether this approach could help future patients.

About this study

In plain language

The PATROL study looks for ways to find prostate cancer earlier in people with gene changes linked to a risk of fast-growing or spreading cancer. It is for people age 40 or older who have a prostate and a confirmed inherited gene change linked or thought to be linked to prostate cancer risk. Researchers study blood, urine, and/or tissue samples to learn more.

This study investigates ways to detect prostate cancer earlier in people at genetic risk for disease that forms, grows, or spreads quickly (aggressive). Studying samples of blood, urine, and/or tissue in the laboratory may help doctors further understand the genetics of prostate cancer and help identify ways to detect cancer earlier, thereby improving treatment and methods of early detection in the future.

Compensation is read from the study's own description and may be missing — always confirm with the study team.

Eligibility

Who can join

  • You have a prostate and are age 40 or older.
  • You have a confirmed harmful inherited gene change in a gene linked or thought to be linked to prostate cancer risk.

Who can't join

  • You have been diagnosed with prostate cancer before.
  • A health condition makes any study procedure unsafe for you, such as taking a small tissue sample from the prostate.
  • In the past 12 months, you had treatment meant to cure any cancer other than non-melanoma skin cancer.
  • You have taken part, or are taking part, in a trial testing ways to prevent cancer in people with inherited gene changes linked to higher prostate cancer risk.
  • You cannot give written consent to join the study.
  • You cannot or do not want to complete the care and procedures required by the study.

Simplified for readability. The official criteria below are what the study team uses.

Official eligibility criteria

Inclusion Criteria: * People with prostates ≥40 years of age * Documented germline pathogenic variant in known or suspected genes associated with prostate cancer risk. Exclusion Criteria: * Prior diagnosis of prostate cancer * Medical contraindication to any of the study procedures (e.g., prostate biopsy) * For all cancer types except non-melanoma skin cancer, any cancer treatment with curative intent within the past 12 months (e.g., surgery, radiation, chemotherapy, immunotherapy) * Prior or concurrent participation in an interventional clinical trial aimed at preventing cancer for people with germline variants associated with increased prostate cancer risk * Unable to provide written informed consent * Unable or unwilling to complete clinical care and study procedures as indicated by the study protocol.

Study sites (8)

CA

IL

MA

  • Massachusetts General Hospital · Boston, MA 02114Keyan Salari, MD, PhD · Principal investigatorMore trials in Boston

OR

PA

TX

WA